Mayne Builds Oncology Portfolio Through Acquisition Of SuperGen’s Nipent
SuperGen said the firms will likely sign additional agreements for other oncology products, including Mitozytrex.
SuperGen said the firms will likely sign additional agreements for other oncology products, including Mitozytrex.